NOVAVAX INC. overview

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA PR Newswire GAITHERSBURG, Md., April 15, 2025 Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine Full results will be submitted for publication later this year GAITHERSBURG, Md. , April 15, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today...

Novavax Announces Changes to Board of Directors PR Newswire GAITHERSBURG, Md., March 11, 2025 James Young , PhD retires as Chair of the Board, Margaret McGlynn , RPh, appointed John Shiver , PhD appointed to board of directors GAITHERSBURG, Md. , March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that James Young , PhD, is retiring as Chair of the Board and Margaret McGlynn , RPh , has been appointed as his successor. The Company also appointed John Shiver , PhD, to its...

Novavax to Participate in Upcoming March Investor Conferences PR Newswire GAITHERSBURG, Md., Feb. 27, 2025 GAITHERSBURG, Md. , Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45 th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 4, 2025 Time: 9:10 – 9:40 a.m. Eastern Time (ET) Location: Boston, MA Conference Event: Investor Meetings Date: Tuesday,...

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Feb. 27, 2025 Transitioned lead commercial responsibility of Nuvaxovid ™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first...

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 PR Newswire GAITHERSBURG, Md., Feb. 20, 2025 GAITHERSBURG, Md. , Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on...

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone PR Newswire GAITHERSBURG, Md., Dec. 13, 2024 Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which...

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza PR Newswire GAITHERSBURG, Md., Dec. 10, 2024 Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Novavax and certain of its officers and/or directors...